+91-8668442535

Necrotizing Fasciitis Treatment Market By Type (Type I Necrotizing Fasciitis Treatment, Type II NF Treatment, Type III NF Treatment, Type IV NF Treatment) By Drug Type (Penicillin G-based NF Treatment Drugs, Carbapenems-based NF Treatment Drugs, Metronidazole-based NF Treatment Drugs Aminoglycoside-based NF Treatment Drugs, Clindamycin-based NF Treatment Drugs, Fluoroconazoles-based NF Treatment Drugs, Other) By Distribution Channel - Growth, Opportunities & Competitive Analysis, 2018 - 2028

About this report

The global Necrotizing Fasciitis Treatment Market report explores the critical analysis of the necrotizing fasciitis treatment industry using key parameters. The report consists of investment strategies, the need for investments in the necrotizing fasciitis treatment industry, and the multiple benefits for investors. Importantly, this report sets out major changes in the global technical regulations for the necrotizing fasciitis treatment industry and how economic and non-economic barriers are helping the necrotizing fasciitis treatment market. 

Moreover, the report analyses the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses such as porter's five forces analysis, PESTEL analysis, value chain analysis, etc.

necrotizing-fasciitis-treatment-market

Key Highlights of the report

How are the major segments performing in the Necrotizing Fasciitis Treatment Market?

  • In 2021, type I necrotizing fasciitis treatment will be the leading segment because there are more cases of type I necrotizing fasciitis.
  • In 2021, the penicillin G-based necrotizing fasciitis treatment drugs segment in the drug type will lead the market since they destroy bacteria or stop their growth; antibiotics are most frequently utilized.
  • In 2021, the necrotizing fasciitis treatment drug sales via hospital pharmacies segment in the end-use industry will lead the market because there will be more hospital pharmacies over the forecasted era. 

Which region dominated the Necrotizing Fasciitis Treatment Market?

In 2021, North America was one of the major contributors to the global Necrotizing Fasciitis Treatment market due to the market for necrotizing fasciitis treatments having large participants and the growing significance of finding and treating rare diseases. The market for necrotizing fasciitis treatments is expected to rise more quickly due to the public's greater awareness of bacterial infections. The United States has the greatest market in this region, followed by Canada, and North America has the largest market share.

What is the competitive environment of the Necrotizing Fasciitis Treatment Market?

Numerous domestic companies enjoy significant market shares in their regions in the global market for necrotizing fasciitis treatments. Consolidation of the market is partly attributable to high research and development costs and the length of the clinical trial procedure. The market for treating necrotizing fasciitis on a global scale is drawing many home producers. The major competitors in the global market for necrotizing fasciitis treatments concentrate on corporate growth and participate in mergers and partnerships.

Executive Summary

What contributes to Necrotizing Fasciitis's increased prevalence?

Necrotizing Fasciitis, often known as flesh-eating illness, is a rare but serious bacterial infection that affects the tissue underneath the skin and nearby organs and muscles. Necrotizing fasciitis develops swiftly after a slight injury. When co-morbid conditions, including immunosuppression, chronic alcoholism, chronic renal failure, liver cirrhosis, and diabetes mellitus, are present, the prognosis for necrotizing fasciitis becomes poor. Necrotizing fasciitis must be diagnosed as soon as possible because any delay could result in more complicated surgery, a higher likelihood of amputation, and a higher mortality rate. 

The infection that causes necrotizing can cause systemic inflammatory response syndrome if left untreated. The market for necrotizing fasciitis therapy will be driven by an increase in the frequency of chronic disease, a greater emphasis on research and development of uncommon diseases, and new technology. Treatment options for necrotizing fasciitis include surgery to remove diseased tissues, antibiotics, and supportive care to manage fluid levels, blood pressure, and organ function.

Which are the key investments by the players in the Necrotizing Fasciitis Treatment Industry Market?

The market for Necrotizing Fasciitis Treatment is expected to be driven shortly by recent developments in drug development, an increase in the number of drugs in clinical trials, and a focus on biological and technological advancements. Substantial R&D efforts, as well as rising government backing, are being made to cure rare diseases. 

Some major players in the Necrotizing Fasciitis Treatment market are GlaxoSmithKline Plc., Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co., Inc, Abbott, Teva Pharmaceutical Industries Ltd, Basilea Pharmaceutica Ltd., MELINTA THERAPEUTICS, Atox Bio, WOCKHARDT, and others.

What are the Major Driving Factors for the Necrotizing Fasciitis Treatment Market?

The market for necrotizing fasciitis therapy will be driven in the future by chronic disease prevalence, the growing emphasis on R&D of uncommon diseases, and the development of new technology. Additionally, major factors that support the growth of the global market include the rising incidence of cancer and diabetes, the steadily aging population, and the rising number of patients with various bacterial illnesses. The market for treating necrotizing fasciitis is expected to rise due to rising awareness, wound and trauma therapy innovations, and breakthroughs in detecting rare diseases. 

What are the Major Risks for the Necrotizing Fasciitis Treatment Market?

Non-steroidal anti-inflammatory drugs (NSAIDs) and steroids are used to suppress a fever, making it harder to diagnose the condition and, lacking defined treatment and diagnostic criteria, impeding the growth of the necrotizing fasciitis treatment market. Due to a lack of awareness about necrotizing fasciitis and the high cost of therapy, the expansion of the market for necrotizing fasciitis treatments is constrained.

Which is the key type in the Necrotizing Fasciitis Treatment Market?

Due to an increase in type I necrotizing fasciitis occurrences, type I necrotizing fasciitis treatment will be the dominant market in 2021. It mainly affects the torso and perineum and is caused by a polymicrobial infection that commonly contains group A streptococci (such as Streptococcus pyogenes) and a combination of aerobic and anaerobic bacteria (e.g., Bacteroides species). These organisms generally spread to subcutaneous tissue following an adjacent lesion or infection.

How is the Necrotizing Fasciitis Treatment Market performing in regions?

In 2021, the global Necrotizing Fasciitis Treatment market was dominated by North America due to the existence of major market participants in necrotizing fasciitis treatment and the growing importance placed on the identification and treatment of rare diseases. Growing public awareness of bacterial infections is expected to hasten the market's expansion for necrotizing fasciitis treatment. The U.S. is the largest market in this region, followed by Canada, and North America accounts for the largest market share. The prevalence of cardiovascular disease has risen in the United States over the past several years. This results from the key risk factors for cardiovascular illnesses, such as obesity and diabetes, which are chronic diseases with an increased prevalence.

Besides, the Asia-Pacific region is expected to grow significantly over the forecast period. The primary factor driving market expansion is the rising prevalence of chronic diseases like diabetes, cancer, and bacterial infections in emerging nations. Due to the growing elderly population, China and India are the two regions with the fastest growing economies. Diabetes is one of the main chronic disorders that affect many patients, which impacts the market's expansion. The market in this area is driven by growing public awareness of infections and the availability of new treatment options. The market is also driven by rising healthcare costs and the general expansion of the diagnostic and treatment sectors of the healthcare industry.

What is the regulatory landscape for the Necrotizing Fasciitis Treatment Market?

There are numerous medication candidates in various phases of clinical trials in the United States. 500 to 1,000 new cases of necrotizing fasciitis are reported in the United States every year, according to the Centers for Disease Control and Prevention (CDC). The market for treating necrotizing fasciitis is anticipated to expand quickly due to government financing for uncommon diseases and clinical trials, the high prevalence of chronic diseases, and improving healthcare infrastructure in emerging nations. Additionally, the demand for research and development of biologics and biosimilars for necrotizing fasciitis is driven by increased healthcare spending.

What is the Market Size of the Necrotizing Fasciitis Treatment regarding value?

The global Necrotizing Fasciitis Treatment Market is anticipated to grow at a substantial CAGR of 4.00% in the upcoming years. The global Necrotizing Fasciitis Treatment industry was estimated to be worth USD 2.2 billion in 2021 and was expected to be worth USD 2.8 billion by 2028.

What are the major players planning for the future of the Necrotizing Fasciitis Treatment Market?

The global market for necrotizing fasciitis therapy is predicted to benefit from an increase in R&D activity and the development of treatment facilities. The market for necrotizing fasciitis treatment is also driven by increased awareness, wound and trauma treatment advancements, and diagnostic innovations for rare diseases.

Segmentation of Global Necrotizing Fasciitis Treatment Market-

Global Necrotizing Fasciitis Treatment Market – By Type

  • Type I Necrotizing Fasciitis Treatment
  • Type II Necrotizing Fasciitis Treatment
  • Type III Necrotizing Fasciitis Treatment
  • Type IV Necrotizing Fasciitis Treatment

Global Necrotizing Fasciitis Treatment Market – By Drug Type

  • Penicillin G-based Necrotizing Fasciitis Treatment Drugs
  • Carbapenems-based Necrotizing Fasciitis Treatment Drugs
  • Metronidazole-based Necrotizing Fasciitis Treatment Drugs
  • Aminoglycoside-based Necrotizing Fasciitis Treatment Drugs
  • Clindamycin-based Necrotizing Fasciitis Treatment Drugs
  • Fluoroconazoles-based Necrotizing Fasciitis Treatment Drugs
  • Other Necrotizing Fasciitis Treatment Drugs

Global Necrotizing Fasciitis Treatment Market – By Distribution Channel

  • Necrotizing Fasciitis Treatment Drug Sales via Hospital Pharmacies
  • Necrotizing Fasciitis Treatment Drug Sales via Retail Pharmacies
  • Necrotizing Fasciitis Treatment Drug Sales via Drug Stores
  • Necrotizing Fasciitis Treatment Drug Sales via E-Commerce Platforms

Global Necrotizing Fasciitis Treatment Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Frequently asked questions about the global Necrotizing Fasciitis Treatment Industry

The global Necrotizing Fasciitis Treatment market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Necrotizing Fasciitis Treatment market in terms of value.

The market for necrotizing fasciitis therapy will be driven in the future by chronic disease prevalence, the growing emphasis on R&D of uncommon diseases, and the development of new technology.

The type I necrotizing fasciitis segment had a significant share in 2021, with more than 30% of the market revenue share.

Penicillin G-based Necrotizing Fasciitis Treatment Drugs segment had a significant share in 2021, with more than 30% of the market revenue share.

Necrotizing Fasciitis Treatment Market Scope

Report Attribute Details
Market Value in 2021 USD 2.2 Bn
Market Value in 2028 USD 2.8 Bn
CAGR 4%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Budget Buying
Executive Summary - Brief Global Market Size - Current & Forecast
Regional Market Size - North America
Country Market Size - US
Company Profile – 1
Trusted By
Godaddy
Published Date:  Sep 2022
Category:  Pharmaceuticals
Report ID:   60625
Report Format:   PDF
Pages:   190
Rating:    4.8 (75)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support